Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting ...

This quarter, we began recognizing revenue from our royalty interest in the Borborema Gold Project, signaling the start of a new, recurring revenue ...